GoodRx (NASDAQ:GDRX) Price Target Raised to $10.00

GoodRx (NASDAQ:GDRX) had its price target hoisted by Barclays from $9.00 to $10.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has an overweight rating on the stock.

Several other brokerages also recently commented on GDRX. The Goldman Sachs Group increased their target price on shares of GoodRx from $6.50 to $7.50 and gave the company a neutral rating in a report on Friday, March 1st. KeyCorp upgraded shares of GoodRx from a sector weight rating to an overweight rating and set a $9.00 price objective for the company in a research note on Wednesday, April 10th. SVB Leerink began coverage on GoodRx in a research note on Monday, February 26th. They issued an outperform rating and a $8.00 target price on the stock. Truist Financial upped their price objective on GoodRx from $7.50 to $8.00 and gave the company a hold rating in a research note on Friday, March 1st. Finally, TD Cowen raised their target price on GoodRx from $14.00 to $16.00 and gave the company a buy rating in a research report on Thursday, May 16th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, GoodRx currently has a consensus rating of Moderate Buy and a consensus price target of $9.11.

GoodRx Price Performance

GDRX stock opened at $7.24 on Monday. The company has a market capitalization of $2.72 billion, a P/E ratio of -723.28, a price-to-earnings-growth ratio of 2.47 and a beta of 1.37. GoodRx has a 52-week low of $4.14 and a 52-week high of $9.37. The business has a 50-day simple moving average of $6.97 and a two-hundred day simple moving average of $6.51. The company has a debt-to-equity ratio of 1.02, a quick ratio of 6.29 and a current ratio of 6.29.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Thursday, February 29th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. The company had revenue of $196.64 million for the quarter, compared to analysts’ expectations of $195.59 million. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. Research analysts expect that GoodRx will post 0.23 EPS for the current fiscal year.

Hedge Funds Weigh In On GoodRx

A number of large investors have recently modified their holdings of the company. Rubric Capital Management LP purchased a new stake in GoodRx in the 4th quarter worth approximately $39,348,000. Fuller & Thaler Asset Management Inc. purchased a new stake in shares of GoodRx in the third quarter worth $8,866,000. Sectoral Asset Management Inc. bought a new stake in GoodRx during the third quarter valued at $5,669,000. Picton Mahoney Asset Management purchased a new position in GoodRx during the first quarter worth about $3,467,000. Finally, Dark Forest Capital Management LP bought a new position in GoodRx in the 3rd quarter worth about $2,454,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.